Lipid management for CVD prevention – what could you do for a patient like Sue? | BJC TV

This site is intended for UK healthcare professionals

This is a promotional video organised and funded by Amgen Ltd, and is intended for UK healthcare professionals only. The British Journal of Cardiology has had no input into the content of the activity.

Click here to access Repatha^® (evolocumab) prescribing information.

Adverse event reporting information can be found at the bottom of the page.

Lipid management for CVD prevention – what could you do for a patient like Sue?

19 March 2025

Sponsored

Speakers

Professor Dev Datta Consultant in Metabolic Medicine, University Hospital of Wales
Professor Afzar Zaman Consultant Interventional Cardiologist, Freeman Hospital Newcastle

In this short video, Professor Dev Datta and Professor Azfar Zaman discuss the case of Sue – a fictional patient with CVD – to explore optimal lipid management, early intervention and the role of injectable lipid-lowering therapies.

Abbreviations

CVD, cardiovascular disease

Categories

Featured videos, Lipids

Click here to access Repatha^® (evolocumab) prescribing information.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to Amgen Limited on +44 (0) 1223 436441.

GBR-145-0125-80009 | March 2025